Beam Therapeutics Inc.

BEAMSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1745999

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$377.7M	$60.9M	$51.8M	$24.0K	$18.0K
Research and Development Expense	$437.4M	$311.6M	$387.1M	$103.2M	$54.6M
Operating Expenses	$554.2M	$399.4M	$444.3M	$132.8M	$75.2M
Operating Income (Loss)	-$176.5M	-$338.5M	-$392.5M	-$132.8M	-$75.2M
Nonoperating Income (Expense)	$45.3M	$78.3M	$21.8M	-$61.8M	-$3.2M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$131.2M	—	—	-$194.6M	—
Income Tax Expense (Benefit)	$1.4M	$3.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.1B	$1.5B	$1.3B	$1.5B	$451.7M
Assets, Current	$878.1M	$1.2B	$1.1B	$1.3B	$308.3M
Cash and Cash Equivalents, at Carrying Value	$435.9M	$232.8M	$560.0M	$162.2M	$37.2M
Liabilities	$370.3M	$478.4M	$608.2M	$647.7M	$206.1M
Liabilities, Current	$182.1M	$205.6M	$223.6M	$213.4M	$102.3M
Accounts Payable, Current	$3.9M	$1.6M	$9.0M	$7.5M	$6.3M
Stockholders' Equity Attributable to Parent	$733.5M	$826.7M	$245.6M	-$201.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$149.2M	$22.5M	-$66.3M	-$95.7M	-$72.0M
Net Cash Provided by (Used in) Investing Activities	$71.8M	-$461.3M	-$294.1M	-$100.1M	-$66.7M
Net Cash Provided by (Used in) Financing Activities	$276.4M	$111.6M	$756.1M	$322.3M	$41.3M
Payments to Acquire Property, Plant, and Equipment	$33.7M	$49.0M	$46.8M	$16.4M	$12.5M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)